Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Aptalis Pharma
ClinicalTrials.gov Identifier:
NCT00559364
First received: November 14, 2007
Last updated: January 27, 2014
Last verified: January 2014
  Purpose

This study assesses the efficacy and safety of Viokase® 16 for the correction of steatorrhea (malabsorption of dietary fats) in patients with a history of exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatectomy. This study is sponsored by Aptalis Pharma (formerly Axcan).


Condition Intervention Phase
Exocrine Pancreatic Insufficiency
Chronic Pancreatitis
Pancreatectomy
Drug: Viokase® 16
Drug: Placebo
Drug: Proton pump inhibitor (PPI)
Drug: Omeprazole
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled, Phase III Study to Assess the Safety and Efficacy of Viokase® 16 for the Correction of Steatorrhea in Patients With Exocrine Pancreatic Insufficiency

Resource links provided by NLM:


Further study details as provided by Aptalis Pharma:

Primary Outcome Measures:
  • Percent Coefficient of Fat Absorption (CFA) [ Time Frame: Day 1 up to Day 4 or Day 5 in inpatient period of treatment phase ] [ Designated as safety issue: No ]
    Percent CFA was calculated as ([fat intake - fat excretion]/fat intake)*100, determined in the stools which was collected from Day 1 to Day 4 or Day 5 during the inpatient period of treatment phase. Mean percent (%) CFA was calculated for Day 1 to Day 4 or Day 5 in inpatient period of treatment phase.


Secondary Outcome Measures:
  • Mean Daily Number of Stools [ Time Frame: Day 1 up to Day 4 or Day 5 in inpatient period of treatment phase ] [ Designated as safety issue: No ]
    Mean daily number of stools of each patient was calculated from frequency of stools by the patient per day. Mean daily number of stools during the collection period (Day 1 to Day 4 or Day 5 in inpatient period of treatment phase) for total patients was summarized.

  • Percentage of Stools Categorized as Per Consistency [ Time Frame: Day 1 up to Day 4 or Day 5 in inpatient period of treatment phase ] [ Designated as safety issue: No ]
    Stool consistency was categorized as hard, formed/normal, soft and watery. Percentage of stools of a specific consistency for each patient was calculated as: (total number of stools of specific consistency during the completed days of the inpatient period/ total number of stools during the completed days of the inpatient period)*100. Mean percentage of stool categorized as per consistency for total patients was summarized.


Enrollment: 50
Study Start Date: November 2007
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Viokase® 16 Drug: Viokase® 16
Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
Drug: Proton pump inhibitor (PPI)
Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
Drug: Omeprazole
Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
Placebo Comparator: Placebo Drug: Placebo
Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
Drug: Proton pump inhibitor (PPI)
Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
Drug: Omeprazole
Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.

Detailed Description:

This study is a Phase III, multicenter, randomized, double-blind, parallel, placebo-controlled study, to assess the efficacy and safety of Viokase® 16 for the correction of steatorrhea in patients with EPI due to CP or pancreatectomy. The study will include the following phases: screening phase (up to 10 days), wash-out phase (6 to 7 days), randomization phase (up to 10 days), and treatment phase (6 to 7 days).

In screening phase, patients will undergo screening procedures prior to entry into the study.

In wash-out phase, stool collection will be performed to allow determination of the baseline CFA.

In randomization phase, patients who qualify for the Treatment Phase (that is, patients who have a CFA% below 80%) will be randomized in the study.

In the treatment phase, patients will be randomized in a 2:1 ratio (Viokase® 16 or Placebo). In treatment phase, stool collection period will be performed to allow determination of the CFA% that will serve to assess the efficacy of Viokase® 16 for the correction of steatorrhea. Follow-up procedures will be scheduled 7 to 10 days after discharge. Patients who do not show abnormal findings, adverse events or concomitant medications during the treatment phase will be assessed via follow-up telephone call. Patients who show abnormal findings (physical examination, vital signs, clinical laboratory tests, adverse events, concomitant medications) during the treatment phase will complete a follow-up visit.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient must be male or female, aged 18-80 years
  • Patients must have the ability to provide informed consent
  • Female patients of childbearing potential must have a negative pregnancy test at screening, must use adequate contraception prior to and during the study and must agree not to attempt to become pregnant during the study; and female patients of non-childbearing potential must be surgically sterile or postmenopausal for at least 12 consecutive months
  • Patients must have a medical condition compatible with EPI such as chronic pancreatitis or partial or total resection of the pancreas
  • Patients with CP due to alcohol abuse may be included provided they show no clinical symptoms of recent alcohol consumption and no alcohol withdrawal symptoms
  • Patients with CP must have at least one of the following conditions: an abnormal secretin test, diffuse calcification of the pancreas on plain film of the abdomen, an abnormal endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound, an abnormal computed tomography (CT) (dilated main pancreatic duct, atrophy or calcification of the pancreas) or serum trypsin concentration below 20 nanogram per milliliter (ng/mL)
  • Patients must have evidence of EPI as demonstrated by a fecal elastase (FE-1) determination equal to or below 100 microgram/gram (mcg/g) of stools (FE-1 ScheBo test) at screening
  • Patients must have evidence of EPI as manifested by a CFA% below 80% after the wash-out phase
  • Patients must be able to comply with a high-fat diet

Exclusion Criteria:

  • Patients with a known hypersensitivity and/or contraindication to any of the study medications, to their excipients, components or to Federal Food, Drug, and Cosmetic (FD and C) Blue No. 2 dye marker
  • Patients with acute pancreatitis or with an acute exacerbation of CP at screening or within the last 2 weeks before screening
  • Patients with any active or recurrent malignant pancreatic tumor
  • Patients with a history of significant bowel resection
  • Patients with a dysmotility disorder
  • Patients with insufficient body mass (body mass index less than 18)
  • Patient not willing to be off therapeutic doses for at least 7 days prior to study entry and throughout the course of the study, medications or products that could interfere with fecal fat excretion
  • Patients who do not limit alcohol intake to less than or equal to 1 drink per day during screening and randomization phases and patients who do not refrain from drinking during inpatient periods of the study
  • Patients who have been treated with the following drugs within 7 days prior to screening: H2-receptor antagonists, gastrointestinal anticholinergics and antispasmodics
  • Patients known to have a significant medical and/or mental disease that would compromise the patient's welfare or confound the study results
  • Patients with a history of fibrosing colonopathy, cirrhosis of the liver, or portal hypertension
  • Patients who have a condition known to increase fecal fat loss including celiac disease, biliary cancer, biliary stricture, cholelithiasis, Crohn's disease, pancreatic cancer, radiation enteritis, tropical sprue, whipple's disease, lactose intolerance, pseudomembranous colitis
  • Female patients who are pregnant or breastfeeding
  • Patients who have received an investigational drug within 30 days prior to entering the screening phase of the study
  • Patients with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal values or elevated uric acid levels greater than 1.5 times the upper limit of normal values
  • Patients with causes for EPI other than CP and partial/total pancreas resection, example, cystic fibrosis, primary sclerosing cholangitis, hemochromatosis, isolated enzyme deficiency, deficiency in activation of enzymes in the small intestine etc
  • Patients with a history or clinical evidence of any relevant cardio- or cerebrovascular, renal, endocrine, neurologic, infectious, other gastrointestinal, hematological, oncological or psychiatric disease or emotional problems, which, in the opinion of the investigator, would pose a significant risk for the patient, invalidate the giving of informed consent or limit the ability of the patients to comply with study requirements or interfere otherwise with the conduct of the study and the same applies for immunocompromised patients and/or neutropenic patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00559364

Locations
United States, New Hampshire
Darmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Canada, Quebec
Hotel-Dieu de Levis
Levis, Quebec, Canada, G6V 3Z1
Poland
III Oddzial Chorób Wewnetrznych i Gastroenterologii
Bialystok, Poland, 15 950
Akademickie Centrum Kliniczne
Gdansk, Poland, 80 952
Samodzielny Publiczny Centralny
Katowice, Poland, 40 752
Klinika Chorob Wewnetrznych z Poliklinika
Krakow, Poland, 30 901
Uniwersytecki Szpital Kliniczny nr 1 im
Lodz, Poland, 90 153
SP Szpital Kliniczny nr 4 w Lublinie
Lublin, Poland, 20 954
Wojewodzki Szpital Specjalistyczny Nr5
Sosnowiec, Poland, 40 200
SP Szpital Kliniczny nr 1 Klinika Gastroenterologii
Szczecin, Poland, 71 252
Wojewodzki Szpital Brodnowski
Warszawa, Poland, 03 242
Klinika Gastroenterologii i Chorób Przemiany Materii
Warszawa, Poland, 02 097
Klinika Chorob Wewnetrznych i Gastroenterologii
Warszawa, Poland, 02 507
Katedra Klinika Gastroenterologii
Wroclaw, Poland, 50 376
Slovakia
University Hospital Brastislava
Brastislava, Slovakia, 851 07
University Hospital Bratislava
Bratilslava, Slovakia, 826 06
NZZ Management spol.S.r.o.
Nitra, Slovakia, 949 01
Gastro I. s.r.o., Gastroenterologicka
Presov, Slovakia, 080 01
Sponsors and Collaborators
Aptalis Pharma
Investigators
Study Director: Aptalis Medical Information Aptalis Pharma
  More Information

No publications provided

Responsible Party: Aptalis Pharma
ClinicalTrials.gov Identifier: NCT00559364     History of Changes
Other Study ID Numbers: VIO16EPI07-01
Study First Received: November 14, 2007
Results First Received: January 27, 2014
Last Updated: January 27, 2014
Health Authority: United States: Institutional Review Board
Germany: Federal Institute for Drugs and Medical Devices
Canada: Health Canada
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products

Additional relevant MeSH terms:
Exocrine Pancreatic Insufficiency
Pancreatitis
Steatorrhea
Pancreatitis, Chronic
Pancreatic Diseases
Digestive System Diseases
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Metabolic Diseases
Omeprazole
Proton Pump Inhibitors
Pancreatin
Pancrelipase
Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 26, 2014